Notably, as metabolic disorders are frequently associated with low IGF-1 levels in subjects with MetS, it could be hypothesized that IGF-1 is probably not involved as a proliferation inducer but might have other autocrine and/or paracrine actions. This evidence concerns the gene IGF1 and metabolic disease.